| Policy |
 |
 |
|
Comparative Effectiveness OVERVIEW: Comparative Effectiveness Research Provisions of the American Recovery and Reinvestment Act of 2009 On February 17, 2009, President Obama signed into law the American Recovery and Reinvestment Act of 2009, commonly referred to as the media as the Stimulus Bill.
Among its many provisions, the Act provided $1.1 billion for comparative effectiveness research (CER), $400 million of which went to the National Institutes of Health.. This expansion of funding for CER, the largest ever federal investment in CER, carries significant potential opportunities for industry, patients, and doctors.
A relatively new but increasingly important concept, comparative effectiveness research (CER) aims to help make healthcare more personalized, safer, efficient and effective. CER, also called Patient-Centered Outcomes Research, seeks to evaluate the impact of different options for diagnosing, treating or managing a given condition in a particular patient group. Comparative effectiveness researchers are looking beyond the tightly controlled conditions and often homogenous populations found in clinical trials to determine how diagnostics and treatments are being used—and what impact they are having—in real world settings among diverse patients.
Drug Safety & Drug Efficacy- Two Sides of The Same Coin The following document represents the collective view of expert academic scientists and clinicians, research advocates, and representatives of the patient community. This committee was convened in order to recommend ways in which policy makers in the United States Congress and the United States Food and Drug Administration (FDA) could further strengthen product evaluation.
Individuals on this panel have expert knowledge of FDA processes, drug safety, product development, and scientifi c and clinical research. They have volunteered their time and expertise for the benefit of the patients and the public.
Download the full report here
 |